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A B S T R A C T
The a4 subunit gene (CHRNA4) of the neuronal nicotinic acetylcholine receptor (nAChR), linked to an
idiopathic partial epilepsy, autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), may also play
a key role in the development of the idiopathic generalized epilepsy syndrome (IGE), juvenile myoclonic
epilepsy (JME). This study was designed to explore an association of four polymorphisms of the CHRNA4
with JME in Polish children and young patients. The study included 92 JME patients and 222 unrelated
healthy individuals. In each group the frequencies of the CHRNA4 c.555C>T, c.594C>T, 1674+11C>T, and
1674+14A>G polymorphisms were determined using PCR-RFLP analyses. An association between the
1674+11C>T polymorphism of the CHRNA4 and JME was evidenced. Allele T (the risk factor) appeared
with a signiﬁcantly higher frequency in the JME patients than in the controls (p = 0.0299). The patients
harboring the 1674+11CT+TT genotypes showed an increased risk of JME (CT+TT versus CC: OR = 1.925;
95% CI = 1.021–3.629; p = 0.0408). No association was found for the other CHRNA4 polymorphisms
tested. The CHRNA4 1674+11C>T polymorphismmay be a susceptibility factor for epilepsy, and its higher
frequency in patients with juvenile myoclonic epilepsy suggests that the CHRNA4 may be one of the
candidate genes for this epileptic syndrome.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Idiopathic generalized epilepsies (IGEs) belong to a group of
epilepsies with no apparent structural brain damage or neurolo-
gical abnormalities, and they are mainly due to genetic factors.
Patients with IGEs are prone to recurrent seizures, which occur
both in childhood and in adolescence. Common IGE forms, such as:
juvenile myoclonic epilepsy (JME), childhood absence epilepsy
(CAE), juvenileabsenceepilepsy (JAE), andepilepsywithgeneralized
tonic–clonic seizures (EGTCS), follow complex inheritance pat-
terns.1 In most cases identiﬁcation of genes that underlie predis-
position to IGEs is difﬁcult because of clinical and genetic
heterogeneity of this group of epilepsies,2 and only a few
susceptibility genes have been identiﬁed so far.2–4 Among four
IGE subtypes, JME appears genetically more distinct, and in many
families autosomaldominant inheritance isapparent.4 Thisepileptic
syndrome is characterized by myoclonic tonic–clonic and absence
seizures. It has been found that the risk of developing either JME or
related IGEs ishigher in relatives ofprobandswith JME, anddifferent
subtypes of IGE may coexist within a single family.2,5* Corresponding author. Tel.: +48 61 8546515; fax: +48 61 8546510.
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were tested for linkage to the juvenile myoclonic epilepsy and
strong evidence had been presented that the EJM2 locus, in which
the gene encoding the a7 subunit (CHRNA7) is located, contributes
to the genetic susceptibility to the JME trait.6,7 Mutations of the ion
channel genes encoding subunits of nAChR are associated with the
familial forms of partial epilepsies classiﬁed as autosomal
dominant nocturnal frontal lobe epilepsy (ADNFLE), but some
polymorphisms of the gene coding for the a4 subunit (CHRNA4)
also confer genetic susceptibility to the common subtypes of IGE.8–
11 Suggestive evidence for the Caucasian population came fromone
of the CHRNA4 polymorphisms, c.594C>T (SNP 1044394), inves-
tigated in a group of IGE probands, comprising CAE, JAE and JME
patients.8 Recently, another silent polymorphism within the
CHRNA4 (Ser543Ser) have been linked to the group of IGEs in
the Taiwanese population.9 Two other CHRNA4 polymorphisms,
1674+11C>T (SNP 45442394) and 1674+14A>G (SNP 3827020),
located within intron5 of the CHRNA4, are distinguishable by the
presence of restriction sites for SsiI or Sty.12 It has been suggested
that the CHRNA4 polymorphisms or putative sequence variants
situated near the CHRNA4 locus, confer susceptibility to the
common IGE syndromes. In view of a possible association between
the CHRNA4 variants and IGEs, we decided to analyze four of these
polymorphisms in our sample comprising the JME patients.vier Ltd. All rights reserved.
Table 1
Localization, genotype and allele frequencies of the CHRNA4 polymorphisms in JME patients and control subjects.
Polymorphism position Genotypes Number of genotypes (%) Genotype pVAL (x2 test) Alleles Number of alleles (%) Allele pVAL
JME Controls JME Controls x2 test Fisher’s exact test
555 bp FokI (Exon5) CC 76 (83%) 110 (80%) 0.676 C 168 (0.91) 246 (0.90) 0.587 0.630
CT 16 (17%) 26 (19%) T 16 (0.09) 28 (0.10)
TT 0 1 (1%) S 184 274
594 bp CfoI (Exon5) CC 83 (90%) 120 (88%) 0.539 C 175 (0.95) 257 (0.94) 0.550 0.680
CT 9 (10%) 17 (12%) T 9 (0.05) 17 (0.06)
TT 0 0 S 184 274
1674+11 bp SsiI (Intron5) CC 72 (78%) 194 (87%) 0.041* C 163 (0.89) 416 (0.94) 0.029* 0.034*
CT 19 (21%) 28 (13%) T 21 (0.11) 28 (0.06)
TT 1 (1%) 0 S 184 444
1674+14 bp StyI (Intron5) AA 31 (34%) 52 (38%) 0.722 A 114 (0.62) 174 (0.64) 0.737 0.768
AG 52 (56%) 70 (51%) G 70 (0.38) 100 (0.36)
GG 9 (10%) 15(11%) S 184 274
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2.1. Subjects
The subjects of the study were 92 unrelated Polish children and
young patients in whom JME was diagnosed, and 222 healthy
volunteers. Probands were patients of the Department of Devel-
opmental Neurology of University of Medical Sciences in Poznan.
All patients were Caucasians aged 6–26 years, and fulﬁlled
diagnostic criteria for JME of the International Classiﬁcation of
Epileptic Syndromes. Healthy individuals, born in Poland, aged 15–
35 with no history of any epilepsy syndromes and neurological
disorders served as controls. Written consents from all adult
patients and parents of the children were obtained, and the local
Ethic Review Committee approved the study protocol.
2.2. Genotyping
The CHRNA4 genotypes were determined by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
assay, using published PCR primers.12 The ampliﬁcation was
followed by restriction digestion with the FokI (c.555C>T; SNP
1044393), CfoI (c.594C>T; SNP 1044394), SsiI (1674+11C>T; SNP
45442394), and StyI (1674+14A>G; SNP 3827020). Digested PCR
products were directly analyzed by electrophoresis either on 2%
agarose or 10% polyacrylamide gels, and each allele was identiﬁed
according to its size.
2.3. Statistical analysis
The genotype and allele frequencies of the CHRNA4 polymorph-
isms in the JME patients were compared with the healthy
individuals using a case–control study design. Signiﬁcance was
evaluated by Chi-square or Fisher exact test. Odds ratios and 95%
conﬁdence intervals were estimated using an online implementa-
tion for deviation from Hardy–Weinberg equilibrium and tests forTable 2
The tests for associationa of CHRNA4 polymorphisms in JME patients and control subje
Polymorphism Allele freq. difference Heterozygous
CHRNA4 Ssi 1674+11 Risk allele T
JME [C] vs. [T] [CC] vs. [CT]
Odds ratio = 1.914,
C.I. = [1.057–3.467],
x2 = 4.72, p = 0.02988
Odds ratio = 1.
C.I. = [0.962–3
x2 = 3.46, p = 0
a The tests for association were adapted from http://ihg2.helmholtz-muenchen.de/cgassociation (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/
hwa1.pl). In all cases, p < 0.05 was considered as statistically
signiﬁcant.
3. Results
The data for genotype distribution and allele frequencies of
CHRNA4 c.555C>T, c.594C>T, 1674+11C>T, and 1674+14A>G
polymorphisms for the patients and the controls are shown in
Table 1. Distribution of these polymorphisms was consistent with
Hardy–Weinberg equilibrium in the patients and in the control
group. No signiﬁcant differences were observed in either the
frequency of the CHRNA4 c.555C>T, c.594C>T, and 1674+14A>G
genotypes or alleles between the patients and the controls. The CC,
CT and TT genotype distribution of the CHRNA4 c.555C>T
polymorphismwas, respectively, 83%, 17%, and 0% for the patients,
and 80%, 19%, and 1% for the controls. There were no TT genotypes
in the patients. The derived allele frequencies for the C and T alleles
were 91% and 9% in the patients, and 90% and 10% in the controls.
Studies on the c.594C>T CHRNA4 polymorphism showed similar
results (see Table 1). The genotype frequencies in the probands
were 90% (CC) and 10% (CT), and in the controls: 88% (CC) and 12%
(CT). No 594TT homozygotes were identiﬁed in each group. The
allele frequencies in the patients and the controls were 95% (C) and
5% (T), and 94% (C), and 6% (T), respectively. Analyses of the
1674+14A>G polymorphism also revealed that genotype and allelic
frequency did not differ between the patients and the control
group (see Table 1).
On the contrary, the 1674+11C>T polymorphism in the patients
showed a signiﬁcant difference when compared to the healthy
individuals. The frequency of the T allele of the 1674+11C>T
polymorphism in the JME groupwas higher than that in the control
group (p = 0.0299). Moreover, no TT genotype was found among
the healthy individuals (see Table 1). We also undertook the test
for association, using the 1674+11T as a risk allele (see Table 2). The
odds ratios (ORs) and the conﬁdence intervals (CIs) were calculatedcts.
Homozygous Allele positivity




Odds ratio = 8.048,
C.I. = [0.324–199.818],
x2 = 2.67, p = 0.10242
Odds ratio = 1.925,
C.I. = [1.021–3.629],
x2 = 4.18, p = 0.04082
i-bin/hw/hwa2.pl.
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genotype of higher frequency among controls, whichwas set as the
reference genotype.When the 1674+11CC genotypewas used as the
reference, the combined 1674+11CT+TT genotypes were associated
with signiﬁcantly higher risk of JME (OR = 1.925; CI = 1.021–3.629,
p = 0.0408).
4. Discussion
Genes encoding the nAChR subunits had recently emerged as
the candidates for idiopathic epilepsies. Signiﬁcant evidence for
linkage of JME was found to polymorphic loci within the region on
chromosome 15q14, in which the CHRNA7 is localized.6,7 Two
independent investigations, however, have failed to conﬁrm these
ﬁndings.13,14 On the other hand, several mutations of the CHRNA4
gene were associated with ADNFLE.15 Since the c.851C>T (S284L)
mutation of the CHRNA4was identiﬁed in a Caucasian family with
ADNFLE,16 we decided to study the linkage of four CHRNA4
polymorphisms with JME in a sample from the Polish population.
Two of these polymorphisms, c.555C>T and c.594C>T, are located
in exon5, and two other, 1674+11C>T and 1674+14A>G, are within
intron5 of the CHRNA4. To date, all of these polymorphisms, except
the 1674+11C>T, had been studied in epilepsy, and in a single
report.8 only one, the c.594C>T polymorphism, was associated
with IGE. In this study, the c.594C>T polymorphismhad previously
been associated with the common subtypes of IGE, but no
distinction between JME or absence epilepsies was made.8 The
frequency of the T-allele was higher in the entire group of IGE
patients (0.085) compared to the healthy individuals (0.027).
However, case–control and family-based study, made by Chioza
et al.10 in 182 Caucasian patients with IGEs (JME, JAE and CAE), as
well as in 178 controls, has not implicated the CHRNA4 c.594C>T
polymorphism in susceptibility to epilepsy.10 In this study, the
allele frequencies of the 594T polymorphism in IGE probands and
controls were virtually the same (0.05 and 0.04, respectively). In
our study no signiﬁcant differences in the T-allele distribution
between the patients (0.05) and the control group (0.06) were
discerned, and no homozygous 594TT genotype was found in the
patients as well as in the control group. Also the c.555C>T
polymorphism was not associated with JME, one of the IGE
subtypes, similar to that reported for the Kuwaiti Arab children
with IGEs (CC = 85%, CT = 14%, TT = 1%).11 The allele frequencies of
the c.555C>T polymorphism in our control group (C = 90%,
T = 10%), however, were lower than that reported in other
Caucasian populations, where the C allele was found in 70% and
the T allele in 30% of cases.17 The genotype frequencies of yet
another polymorphism, 1674+14A>G, located 14 bp into intron5,
were similar in the IGE patients and controls in the earlier study.10
In our study, there were also no differences between the genotype
frequencies of this polymorphism in the JME patients, and the
controls. However, the genotype frequencies in the controls
obtained (AA = 38%, AG = 51% and GG = 11%) were different from
those originally reported by Chioza et al.10 (AA = 77%, AG = 18% and
GG = 5%). These discrepancies, however, might be due to different
populations studied.
In our study, another polymorphic variant, 1674+11C>T, which
was never investigated in epileptic syndromes so far, located 11 bp
into intron5 of the CHRNA4was analyzed. This polymorphism was
recently detected in the patients with Alzheimer’s disease, but didnot have any signiﬁcant associationwith AD.12 On the contrary, the
association between CHRNA4 1674+11C>T polymorphism and JME
was evidenced. We found that the 1674+11T allele appeared with a
signiﬁcantly higher frequency in the patients than in the control
group and the patients with the 1674+11CT+TT genotypes showed
increased risk of JME, indicating the 1674+11T allele as a risk factor
for this formof epilepsy. This demonstrated that the CHRNA4might
be yet another important gene connected with JME. Further
investigations are required, however, to substantiate our ﬁndings.
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